Cronos Group

Toronto, CanadaFounded 2012

Producer & Grower NASDAQ: CRON www.thecronosgroup.com

Share:X / Twitter LinkedIn Suggest a correction

About Cronos Group

Cronos Group is a Toronto-headquartered cannabis company backed by tobacco giant Altria Group, which invested CAD $2.4 billion for a 45% stake. The company focuses on innovative cannabinoid research and product development, with operations in Canada and Israel.

Key Facts

1Altria Group, maker of Marlboro cigarettes, invested CAD $2.4 billion for a 45% stake in 2019
2Invested in Ginkgo Bioworks partnership for fermentation-based cannabinoid production
3Operates through subsidiary Peace Naturals, one of the first licensed producers in Canada
4Holds strategic cannabis operations in Israel through Cronos Israel

Latest News

Major Cannabis Stocks Plunge on Rescheduling Reality Check

5d ago

TLRY, CGC, ACB, CRON, and OGI tumble as investors reassess limited impact of federal cannabis reclassification on Canadian operators and market fundamentals.

Cannabis Stocks Plunge as Rescheduling Optimism Fades

5d ago

Major cannabis operators including TLRY, CGC, and ACB tumble as investors reassess limited impact from federal reclassification prospects.

Cronos Group Surges 970% Above Average Volume Amid $2.86 Trading

6d ago

CRON experiences massive trading activity with 11.6M shares changing hands, representing a 10.7x spike from its typical volume despite 3.87% price decline.

View all CRON news

Frequently Asked Questions

Why did Altria invest in Cronos?

Altria, the tobacco giant behind Marlboro, invested in Cronos to gain a foothold in the cannabis industry as a potential growth avenue given declining cigarette sales. The deal gave Cronos significant capital for R&D and expansion.

What is Cronos doing with biosynthesis?

Cronos partnered with Ginkgo Bioworks to develop fermentation-based production of rare cannabinoids, aiming to produce cannabinoids more efficiently than traditional cultivation methods.